LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with ...
Hosted on MSN3mon
Positive Phase III results for linerixibat in cholestatic pruritus treatment for PBC patientsResearchers are looking to establish the safety and efficacy of linerixibat – an investigational targeted inhibitor of the ileal bile acid transporter (IBAT) – for the treatment of cholestatic ...
Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback